Long-Term Partnership: Bicycle Therapeutics has signed a 15-year contract with the UK Nuclear Decommissioning Authority, securing access to up to 400 tonnes of reprocessed uranium, which will provide a sustainable raw material supply for its potential lifesaving therapies, significantly enhancing the company's R&D capabilities.
Radioisotope Development: Through collaboration with the UK National Nuclear Laboratory, Bicycle plans to extract 228Th from the reprocessed uranium, further processing it into a 212Pb generator, with the potential to deliver tens of thousands of doses of 212Pb annually, advancing targeted cancer therapies.
Customized Generator: Bicycle has partnered with SpectronRx to develop a bespoke 212Pb generator, with initial quantities of 212Pb successfully produced, which will provide strong support for the company's competitive position in the radiopharmaceutical market.
Strategic Investment Outlook: The CEO of Bicycle stated that these collaborations demonstrate the company's potential in radiopharmaceutical R&D, with expectations to advance its BRC product line and present initial human imaging data in the first half of 2026, further solidifying its market position.
BCYC
$7.33+Infinity%1D
Analyst Views on BCYC
Wall Street analysts forecast BCYC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCYC is 22.29 USD with a low forecast of 11.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast BCYC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCYC is 22.29 USD with a low forecast of 11.00 USD and a high forecast of 44.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 7.450
Low
11.00
Averages
22.29
High
44.00
Current: 7.450
Low
11.00
Averages
22.29
High
44.00
Truist
Hold
initiated
$10
2025-11-24
Reason
Truist
Price Target
$10
2025-11-24
initiated
Hold
Reason
Truist initiated coverage of Bicycle Therapeutics with a Hold rating and $10 price target. The time to market and ultimate market potential remains uncertain for Zele, pending further visibility from the Phase 2/3 Duravelo-2 trial, particularly as Padcev continues to entrench as a widely adopted standard of care, the analyst tells investors in a research note. Truist adds that it sees broader value from Bicycle's pipeline, including BT5528, and the radiopharma franchise, though these programs remain early in development and are unlikely to yield meaningful near-term contribution.
RBC Capital
Leonid Timashev
Outperform -> Sector Perform
downgrade
$27 -> $11
2025-10-31
Reason
RBC Capital
Leonid Timashev
Price Target
$27 -> $11
2025-10-31
downgrade
Outperform -> Sector Perform
Reason
RBC Capital analyst Leonid Timashev last night downgraded Bicycle Therapeutics to Sector Perform from Outperform with a price target of $11, down from $27, following the Q3 report. The company's pipeline programs are taking more time to reach inflection points, the analyst tells investors in a research note. RBC thinks Bicycle's near-term updates may not provide substantial enough data to de-risk its programs and drive share upside. As such, the firm moves to the sidelines pending greater visibility into the path forward for zelenectide and BT5528.
Citizens JMP
Reni Benjamin
Outperform
maintain
$10 -> $12
2025-10-31
Reason
Citizens JMP
Reni Benjamin
Price Target
$10 -> $12
2025-10-31
maintain
Outperform
Reason
Citizens JMP analyst Reni Benjamin raised the firm's price target on Bicycle Therapeutics to $12 from $10 and keeps an Outperform rating on the shares. Bicycle reported Q3 financial results and updated corporate milestones, including regulatory feedback regarding dose selection for the pivotal Duravelo-2 now expected in 1Q26, the analyst tells investors in a research note. Bicycle shares have upside from current levels, with the zele pivotal trial enrolling, multiple partnerships secured, and a strong cash position of $648.3M, the firm says.
RBC Capital
Leonid Timashev
Outperform -> Sector Perform
downgrade
$27 -> $11
2025-10-30
Reason
RBC Capital
Leonid Timashev
Price Target
$27 -> $11
2025-10-30
downgrade
Outperform -> Sector Perform
Reason
RBC Capital analyst Leonid Timashev downgraded Bicycle Therapeutics to Sector Perform from Outperform with a price target of $11, down from $27.
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
